Sort
8,912 grants matching “sars cov 2”
Columbia University/Aga Khan University Global Network Research Unit
$481,651Robert L Goldenberg · Columbia University Health Sciences · UG1 · FY2025 · HD
Synthetically Accessible Virtual Inventory (SAVI)
$481,579Marc Nicklaus · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Crossing scales to predict and prevent bat virus zoonoses in a Madagascar ecosystem
$481,500Cara Brook · University Of California Berkeley · DP2 · FY2025 · AI
Development of a Video-based Personal Protective Equipment Monitoring System
$481,327Randall S. Burd · Children'S Research Institute · R01 · FY2024 · EB
The role of TRIM2 and SIRPA in New World Arenavirus entry
$481,188Susan R Ross · University Of Illinois At Chicago · R01 · FY2025 · AI
Project 4: Epigenetic modifiers of regulatory T cell function following viral pneumonia
$480,936Benjamin David Singer · Northwestern University At Chicago · P01 · FY2024 · HL
Administrative Core
$480,869John P. Kirwan · Lsu Pennington Biomedical Research Ctr · U54 · FY2022 · GM
SARS Receptor Characterization/Virus Binding Blockagage
$480,702Kathryn V Holmes · University Of Colorado Denver · P01 · FY2007 · AI
Development of a Video-based Personal Protective Equipment Monitoring System
$480,474Randall S. Burd · Children'S Research Institute · R01 · FY2025 · EB
Innate Determinants of Microbial Immunity
$480,448Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Risk of Viral Emergence from Bats
$480,423Peter Daszak · Ecohealth Alliance, Inc. · R01 · FY2010 · AI
The role of TRIM2 and SIRPA in New World Arenavirus entry
$480,006Susan R Ross · University Of Illinois At Chicago · R01 · FY2024 · AI
Plasmon-enhanced Lateral Flow Assay for Multiplexed Detection of SARS-CoV-2 RNA and Antigens in Point-of-Care Settings
$480,000Srikanth Singamaneni · Washington University · · FY2022 · ENG
Systems investigation of vaccine responses in aging and frailty
$479,815Albert C Shaw · Yale University · U19 · FY2023 · AI
Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir
$479,695Bingfang Yan · University Of Cincinnati · R01 · FY2024 · AI
Administrative Core
$479,565John P. Kirwan · Lsu Pennington Biomedical Research Ctr · U54 · FY2024 · GM
Defining the Translocation Mechanisms of SARS-CoV-2 nsp13 Helicase to Aid in Antiviral Development
$479,232Martin McCullagh · Oklahoma State University Stillwater · R01 · FY2021 · AI
Comprehensive Determination of Isoprostanoid Metabolism
$478,765Ginger Lohr Milne · Vanderbilt University Medical Center · R21 · FY2024 · AG
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
$478,737Feng Guo · University Of California Los Angeles · R01 · FY2025 · AI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
$478,737Feng Guo · University Of California Los Angeles · R01 · FY2022 · AI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
$478,737Feng Guo · University Of California Los Angeles · R01 · FY2023 · AI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
$478,737Feng Guo · University Of California Los Angeles · R01 · FY2024 · AI
Spatial-Temporal Dissection of Stratified Host Tissue Responses to Severe acute respiratory syndrome-related coronaviruses in situ to Understand Intra-host Pathogenesis
$478,605Sizun Jiang · Beth Israel Deaconess Medical Center · DP2 · FY2024 · AI
Unraveling Cytotoxic and Thrombotic Signals in COVID-19
$478,455Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Host factors contributing to susceptibility to COVID-19 disease
$478,359Helen Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI